论文部分内容阅读
紫杉醇是从紫杉树皮中分离出的一种新型抗肿瘤药物,其化学结构新颖,作用机理独特,它可以特异地结合于微管,导致微管聚合成团块和成束,抑制微管网的正常重组.临床研究表明紫杉醇对人卵巢癌,乳腺癌及黑色素瘤具有一定疗效,为观察紫杉醇对化疗失败的晚期肿瘤的疗效,我们对18例应用常规化疗失败的患者改用紫杉醇为主的方案治疗,现将结果报告如下:1 材料和方法1.1 一般资料18例患者均为临床Ⅳ期恶性肿瘤,其中胃癌2例,肠癌5例,肺癌7例,乳腺癌4例.男性12例,女性6例,平均龄59.4岁.Karnofoky评分均≥80分.所有患者既往均接受过
Paclitaxel is a novel antitumor drug isolated from the bark of yew. Its chemical structure is novel and its mechanism of action is unique. It can specifically bind to microtubules, resulting in the polymerization of microtubules into clumps and bundles, and inhibiting microtubules. The normal reorganization of the network. Clinical studies have shown that paclitaxel has a certain effect on human ovarian cancer, breast cancer and melanoma. To observe the efficacy of paclitaxel on late-stage chemotherapy failure, we switched to paclitaxel in 18 patients who failed conventional chemotherapy. The treatment of the program, the results are reported as follows: 1 Materials and Methods 1.1 General Information 18 patients were clinical stage IV malignant tumors, including 2 cases of gastric cancer, 5 cases of colorectal cancer, 7 cases of lung cancer, 4 cases of breast cancer. , 6 females, mean age 59.4 years, Karnofoky score ≥ 80 points. All patients have been previously received